The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: Implications for prognosis

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 11, 2008, Pages 1841-1850

  Boos, C J ^a   Balakrishnan, B ^a   Blann, A D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Acute coronary syndromes; Apoptosis; Circulating endothelial cells; Endothelium; Fas ligand; Outcomes; Soluble E selectin; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD CELLS; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; ENDOTHELIUM; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VON WILLEBRAND FACTOR;

EID: 54149115478     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03148.x     Document Type: Article

References (38)

1. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol 2000; 15: 409-15.
2. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006; 48: 1538-47.
3. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: Relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004; 110: 1794-8.
4. Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: Two sides of the same coin, or two different coins? Atherosclerosis 2006; 188: 12-8.
5. Nadar SK, Lip GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005; 94: 707-12.
6. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-32.
7. Quilici J, Banzet N, Paule P, Meynard JB, Mutin M, Bonnet JL, Ambrosi P, Sampol J, Dignat-George F. Circulating endothelial cell count as a diagnostic marker for non-ST-elevation acute coronary syndromes. Circulation 2004; 110: 1586-91.
8. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93: 2951-8.
9. Boos CJ, Soor SK, Kang D, Lip GY. Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. Eur Heart J 2007; 28: 1092-101.
10. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: A novel marker of endothelial damage. Clin Chim Acta 2006; 373: 17-26.
11. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-62.
12. Wang C, Li H, Fu P, Zhang S, Xiu R. Serum C-reactive protein and circulating endothelial cells in patients with acute myocardial infarction. Clin Hemorheol Microcirc 2005; 32: 287-96.
13. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 33: 1673-90.
14. Ohtsuka T, Hamada M, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Ohtani T, Honda T, Hiwada K. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis 1999; 10: 221-5.
15. Hou YP, Wu JL, Fan Q, Liu MB, Yin BL, Zhang L. Plasma concentration of Fas/Fas ligand and left ventricular function in response to metoprolol in conjunction with standard treatment. Clin Sci 2007; 112: 299-304.
16. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Relation between circulating soluble Fas ligand and subsequent ventricular remodelling following myocardial infarction. Heart 2003; 89: 339-41.
17. Zhang L, Zhang L, Li YH, Zhang HY, Chen ML, Gao MM, Hu AH, Yang HS, Yang HS. High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction. Eur J Clin Invest 2005; 35: 164-70.
18. Shimizu M, Fukuo K, Nagata S, Suhara T, Okuro M, Fujii K, Higashino Y, Mogi M, Hatanaka Y, Ogihara T. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002; 39: 585-90.
19. van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
20. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
21. Boos CJ, Lane DA, Kang D, Goon PKY, Blann AD, Lip GYH. Temporal and venepuncture-related decline in Circulating Endothelial Cell capture from mixed venous blood. J Thromb Thrombolysis 2006; 22: 125-31.
22. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: Proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4: 671-7.
23. Bland MJ, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
24. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
25. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10year follow up of survivors of acute myocardial infarction. Heart 1998; 80: 334-7.
26. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke 2007; 38: 1873-80.
27. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.
28. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: A double-edged immunomodulator. Blood 2005; 105: 1396-404.
29. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by FAS/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-30.
30. Proussakova OV, Rabaya NA, Moshnikova AB, Telegina ES, Turanov A, Nanazashvili MG, Beletsky IP. Oligomerization of soluble FAS antigen induces its cytotoxicity. J Biol Chem 2003; 278: 36236-41.
31. Mitsiades N, Yu W, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-81.
32. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its propapoptotic activity and loss of liver toxicity. J Exp Med 1998; 8: 1205-13.
33. Nadal C, Maurel J, Gallego R, Castells A, Longaron R, Marmol M, Sanz S, Molina R, Martin-Richard M, Gascon P. FAS/FAS ligand ratio: A marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 2005; 11: 4770-4.
34. Dimmeler S, Hermann C, Zeiher AM. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis? Eur Cytokine Netw 1998; 9: 697-8.
35. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De Muinck E, Wellens HJ, Kemerink GJ, Reutelingsperger CP, Heidendal GA. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356: 209-12.
36. Schmid FX, Vudattu N, Floerchinger B, Hilker M, Eissner G, Hoenicka M, Holler E, Birnbaum DE. Endothelial apoptosis and circulating endothelial cells after bypass grafting with and without cardiopulmonary bypass. Eur J Cardiothorac Surg 2006; 29: 496-500.
37. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007; 71: 105-13.
38. Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb Haemost 2006; 96: 45-52.